New York, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW, LGSTU), a publicly-traded special purpose acquisition company, announced ...
The pro forma equity value of the portion of the combined company attributable to Tevogen Bio Inc (“Tevogen Bio”) stockholders is an expected $1.2 billion. Tevogen Bio is an advanced-stage specialty ...
New York, NY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW), a publicly-traded special purpose acquisition company, today announced ...
New York, NY, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (LGST) (“Semper Paratus”), a publicly traded special purpose acquisition company, today announced the filing of ...
Neither of Tevogen Bio or Semper Paratus gives any assurance that Tevogen Bio or Semper Paratus, or the combined company, will achieve its expectations. These forward-looking statements should not be ...
New York, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW, LGSTU), a publicly-traded special purpose ...
Tevogen Bio and Semper Paratus previously announced, on June 29, 2023, their execution of a definitive business combination agreement. The pro forma equity value of the portion of the combined company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results